Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes.
Beta-blocking drugs have been shown to reduce the overall mortality and risk of sudden cardiac death in survivors of acute myocardial infarction. It is not known whether such an effect is mediated by suppression of ventricular premature complexes (VPCs). The circadian rhythmicity of ventricular arrhythmia can also be suppressed by beta-blocking drugs, and this may help reduce the risk of sudden cardiac death during the morning hours. Recent studies have also shown that beta blockers can provide a safe and effective combination with class IA antiarrhythmic agents when arrhythmias cannot be controlled with class IA agents alone. Sotalol, a nonselective beta antagonist, has unique electrophysiologic properties, and several studies have shown it to be more effective than conventional beta blockers in suppressing ventricular arrhythmias. However, direct comparative studies of the suppression of VPCs are lacking. In a recent double-blind, placebo-controlled, parallel study, the antiarrhythmic effects of sotalol and propranolol were compared in 172 patients with greater than 30 VPCs/hour. After the initial 1-week washout and 1-week placebo period, patients were randomly assigned to either 160 mg of sotalol administered twice daily (76 patients) or 40 mg of propranolol administered 3 times daily (91 patients). Those responding to therapy (decreases greater than 75% VPCs) continued to take these doses, but nonresponders were given higher doses, 320 mg of sotalol twice daily or 80 mg of propranolol 3 times daily, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Medicine, University of California, San Francisco School of Medicine.
P C
PC
Deedwania
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000503:physiopathology; D006352:Heart Ventricles; D006801:Humans; D013015:Sotalol / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D013015:Sotalol